Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Debt (2022 - 2025)

Tarsus Pharmaceuticals (TARS) has 4 years of Total Debt data on record, last reported at $72.4 million in Q4 2025.

  • For Q4 2025, Total Debt rose 0.83% year-over-year to $72.4 million; the TTM value through Dec 2025 reached $72.4 million, up 0.83%, while the annual FY2025 figure was $72.4 million, 0.83% up from the prior year.
  • Total Debt reached $72.4 million in Q4 2025 per TARS's latest filing, roughly flat from $72.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $72.4 million in Q4 2025 and bottomed at $19.2 million in Q1 2022.
  • Average Total Debt over 4 years is $45.0 million, with a median of $29.9 million recorded in 2023.
  • Peak YoY movement for Total Debt: soared 190.88% in 2024, then rose 0.77% in 2025.
  • A 4-year view of Total Debt shows it stood at $19.4 million in 2022, then soared by 53.44% to $29.8 million in 2023, then soared by 140.94% to $71.8 million in 2024, then rose by 0.83% to $72.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $72.4 million in Q4 2025, $72.3 million in Q3 2025, and $72.1 million in Q2 2025.